The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.

Kelvin K H Bao Leone Sutanto Shirley S W Tse Ka Man Cheung Jeffrey C H Chan

JAMA Netw Open

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong.

Published: November 2021

This study looks at how low expression levels affect the progression-free survival of patients with HR+/− metastatic breast cancer.
It focuses on patients who are receiving treatment with CDK4/6 inhibitors, a common therapy for this type of cancer.
The findings could provide insights into the relationship between gene expression and treatment outcomes for these patients.

This cohort study investigates the association between low levels of expression and progression-free survival among patients with HR+/− metastatic breast cancer treated with CDK4/6 inhibitors.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571658	PMC
http://dx.doi.org/10.1001/jamanetworkopen.2021.33132	DOI Listing

Publication Analysis

Top Keywords

metastatic breast

breast cancer

association erbb2-low

erbb2-low expression

expression efficacy

efficacy cyclin-dependent

cyclin-dependent kinase

kinase 4/6

4/6 inhibitor

inhibitor hormone

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!